Von Willebrand screen

Alphabetical Test listing

Von Willebrand screen-507

Von Willebrand screen
Ristocetin CoFactor
VWF antigen
Von Willebrands complex

Reflex criteria:

Decrease in the VWF:RoC and/or the VWF:Agn results will automatically reflex to von Willebrand multimers (CIEP), referred to LabCorp, at an additional charge.

Sodium citrate (Na cit) plasma

Two (2) Lt blue Sodium citrate (Na Cit) - 2.7mL tubes

If the patient has a hematocrit >55, a specially prepared Lt blue Sodium citrate (NaCit) tube must be used in place of the standard Lt blue Sodium citrate (NaCit) tube.

Hematocrit-Anticoagulant adjustments

Two (2) full 2.7mL tubes
One (1) full 2.7mL tube
  • Do not over or under fill tube as the ratio of anticoagulant to whole blood is critical

Coag – tube fill guidelines

  • Immediatley following collection, mix sample thoroughly by gentle inverting 8 - 10 times, to prevent clotting
  • Process Platelet Poor Plasma (P.P.P)
  1. Coag – how to prepare a specimen for special coagulation testing

  • Transfer plasma into an aliquot tube using a spot label "NaCit Plasma P.P.P" to label as platelet poor plasma
  • Freeze immediately, or within two (2) hours of sample collection

Microcentrifuge vial/tube in a Snap cap conical vial/tube and cap (Beaker sites)



Coagulation specimen transport vial/tube  (all other sites)




Frozen - strict

Multimer samples are stabile for 14 days at -70°.

Refrigerated - NO

  • Samples collected in Greiner tubes
  • Improper labeling (unlabeled or mislabeled)
  • Improper anticoagulant
  • Improperly filled (over or underfilled) tube
  • Hemolysis
  • Clotted specimen
  • Delay in transport
  • Improper storage/transport temperature
  • Patient on heparin > 1.0 IU/mL.
AHL - Coagulation/Special Coagulation: V
Mo, We, Fr
1 - 3 days

vWF:RoC - Activity by Ristocetin Cofactor

VWF:Ag - Turbidity of micro particle

FVIII:C - One stage clotting

Component Range
vWF:RCo 50 - 200%
vWF:AG 50 - 200%
FVIII:C 50 - 150%
vWF: RCo/vWF:AG >0.7

Von Willebrand factor activity levels are blood group specific with individuals of 'O' blood type showing lower von Willebrand activity levels than other blood groups.


Von Willebrand disease (VWD) is the most common inherited bleeding disorder. Clinically, it is often characterized by mucocutaneous hemorrhages. The three principle types of VWD are:

  • Type 1 corresponds to a quantitative deficiency of VWF; its transmission is autosomal dominant and is the most frequently encountered (70 – 80%).
  • Type 2 refers to a qualitative deficiency of VWF; the defect is often located in the multimeric structure. Its transmission is autosomal dominant or recessive.
  • Type 3 is characterized by a total absence of VWF in both the plasma and cellular components. Its transmission is autosomal recessive.

Acquired VWF deficiencies may be associated with several clinical states such as in myeloma, lymphoma, systemic lupus erythematosus, hypothyroidism, etc. These cases may be referred to as acquired von Willebrand diseases.
VWF is a protein involved in inflammation. Its level increases when there are damages of the vascular endothelium (post-operative period, infection, cancers, renal or hepatic disorders). Some authors have noted that high vWF levels are encountered during cardiovascular disorders, notably during some types of myocardial infarction.

Acquired von Willebrand Syndrome has been reported rarely with the use of griseofulvin, ciprofloxacin, tetracycline, thrombolytic agents and hydroxyethyl starch.


Additional CPT codes (if appropriate):
86327 - von Willebrand multimer studies